ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $100.69 million. The enterprise value is $106.66 million.
| Market Cap | 100.69M |
| Enterprise Value | 106.66M |
Important Dates
The next confirmed earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.05 million shares outstanding. The number of shares has increased by 6.70% in one year.
| Current Share Class | 9.05M |
| Shares Outstanding | 9.05M |
| Shares Change (YoY) | +6.70% |
| Shares Change (QoQ) | -1.57% |
| Owned by Insiders (%) | 28.16% |
| Owned by Institutions (%) | 19.10% |
| Float | 6.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.36 |
| Forward PS | n/a |
| PB Ratio | 3.46 |
| P/TBV Ratio | 3.47 |
| P/FCF Ratio | 29.83 |
| P/OCF Ratio | 22.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.13, with an EV/FCF ratio of 31.59.
| EV / Earnings | n/a |
| EV / Sales | 3.56 |
| EV / EBITDA | 18.13 |
| EV / EBIT | 32.31 |
| EV / FCF | 31.59 |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.44.
| Current Ratio | 4.82 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 2.01 |
| Debt / FCF | 3.78 |
| Interest Coverage | 7.10 |
Financial Efficiency
Return on equity (ROE) is -1.88% and return on invested capital (ROIC) is 9.23%.
| Return on Equity (ROE) | -1.88% |
| Return on Assets (ROA) | 4.60% |
| Return on Invested Capital (ROIC) | 9.23% |
| Return on Capital Employed (ROCE) | 8.21% |
| Weighted Average Cost of Capital (WACC) | 6.87% |
| Revenue Per Employee | $410,059 |
| Profits Per Employee | -$7,471 |
| Employee Count | 73 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 2.14 |
Taxes
In the past 12 months, ImmuCell has paid $22,188 in taxes.
| Income Tax | 22,188 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.80% in the last 52 weeks. The beta is 0.57, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +77.80% |
| 50-Day Moving Average | 9.83 |
| 200-Day Moving Average | 7.23 |
| Relative Strength Index (RSI) | 58.04 |
| Average Volume (20 Days) | 39,595 |
Short Selling Information
The latest short interest is 18,716, so 0.21% of the outstanding shares have been sold short.
| Short Interest | 18,716 |
| Short Previous Month | 12,281 |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.31% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
In the last 12 months, ImmuCell had revenue of $29.93 million and -$545,403 in losses. Loss per share was -$0.07.
| Revenue | 29.93M |
| Gross Profit | 12.75M |
| Operating Income | 3.30M |
| Pretax Income | -523,215 |
| Net Income | -545,403 |
| EBITDA | 5.88M |
| EBIT | 3.30M |
| Loss Per Share | -$0.07 |
Balance Sheet
The company has $6.81 million in cash and $12.78 million in debt, with a net cash position of -$5.96 million or -$0.66 per share.
| Cash & Cash Equivalents | 6.81M |
| Total Debt | 12.78M |
| Net Cash | -5.96M |
| Net Cash Per Share | -$0.66 |
| Equity (Book Value) | 29.14M |
| Book Value Per Share | 3.22 |
| Working Capital | 14.95M |
Cash Flow
In the last 12 months, operating cash flow was $4.47 million and capital expenditures -$1.10 million, giving a free cash flow of $3.38 million.
| Operating Cash Flow | 4.47M |
| Capital Expenditures | -1.10M |
| Depreciation & Amortization | 2.58M |
| Net Borrowing | -1.50M |
| Free Cash Flow | 3.38M |
| FCF Per Share | $0.37 |
Margins
Gross margin is 42.59%, with operating and profit margins of 11.03% and -1.82%.
| Gross Margin | 42.59% |
| Operating Margin | 11.03% |
| Pretax Margin | -1.75% |
| Profit Margin | -1.82% |
| EBITDA Margin | 19.65% |
| EBIT Margin | 11.03% |
| FCF Margin | 11.28% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.70% |
| Shareholder Yield | n/a |
| Earnings Yield | -0.54% |
| FCF Yield | 3.35% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmuCell has an Altman Z-Score of 3.12 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.12 |
| Piotroski F-Score | 7 |